Core Viewpoint - The company has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodixanol Injection, which enhances its product lineup in the contrast agent segment [1] Group 1: Product Approval - The Iodixanol Injection has been approved as a Class 4 chemical drug, indicating it has passed the consistency evaluation for generic drug quality and efficacy [1] - This approval allows the company to diversify its iodine contrast agent product offerings [1] Group 2: Business Development - The company's subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., is expected to have the raw material for Iodixanol approved for market launch by August 2025 [1] - The business model of "raw material + formulation" for Iodixanol has been established, indicating a comprehensive approach to product development [1] Group 3: Market Strategy - The company plans to actively prepare for the launch of new products and aims to bring them to market as soon as possible [1] - However, the production and sales of these products may face some uncertainties [1]